Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
Company Details
- Employees
- 11
- Founded
- 2020
- Address
- Seattle, Us
- Phone
- 206.519.5300
- in****@****atx.com
- Industry
- Biotechnology
- Website
- deverratx.com
- Keywords
- in clinical practice.
- HQ
- Seattle
Deverra Therapeutics Questions
Deverra Therapeutics's helpline number is 206.519.5300
Deverra Therapeutics's website is deverratx.com
Deverra Therapeutics's LinkedIn profile is https://www.linkedin.com/company/deverra-therapeutics
Deverra Therapeutics has
11 employees.
View email and phone details for 11
employees at Deverra Therapeutics.
Deverra Therapeutics's industry is
Biotechnology
Deverra Therapeutics's top competitors are
Sana Biotechnology, Inc.,
Aptevo Therapeutics Inc,
Blaze Bioscience,
Tune Therapeutics,
Adaptive Biotechnologies Corp.,
T-Cure Bioscience, Inc,
Nohla Therapeutics,
Umoja Biopharma,
Coeptis, Inc,
Sonoma Biotherapeutics, Inc..
Deverra Therapeutics's support email address is info@deverratx.com
Deverra Therapeutics's categories are Biotechnology
Deverra Therapeutics's founding year is 2020
